Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
McKinsey
McKesson
AstraZeneca
Medtronic

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,771,418

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,771,418
Title:Methods for treating complement-associated disorders
Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
Inventor(s): Rother; Russell P. (Oklahoma City, OK), Bedrosian; Camille (Woodbridge, CT), Squinto; Stephen P. (Bethany, CT), Bell; Leonard (Woodbridge, CT)
Assignee: Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:15/243,290
Patent Claims:1. A method for treating antibody-mediated rejection (AMR) in a patient having a kidney transplant, the method comprising intravenously administering to the patient: 1200 mg of eculizumab less than 24 hours before or during the transplant operation and one post-operative dose of eculizumab within 24 hours of the transplant operation; 900 mg of eculizumab once a week for four weeks after the post-operative dose; and 1200 mg of eculizumab on week five after the post-operative dose and bi-weekly thereafter.

2. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain at least 50 .mu.g of eculizumab per milliliter of the patient's blood.

3. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain at least 100 .mu.g of eculizumab per milliliter of the patient's blood.

4. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain a concentration of at least 0.7 molecules of eculizumab per every C5 molecule in the patient's blood.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Harvard Business School
McKinsey
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.